Former Bristol Myers Squibb compatriots are reuniting at Flagship Pioneering. Natural killer cell biotech Acepodia has enlisted AbbVie oncology exec Thorsten Graef as its chief medical officer. And Centessa has called upon a former AstraZeneca heavyweight as its new CMO.
(0)
Centessa Pharmaceuticals ( Centessa ) today announced that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer. Dr. Yver is one of the world s leading drug developers with more than 30 years of global experience in the pharmaceutical industry. We are absolutely thrilled to welcome Antoine to our team as CMO, said Saurabh Saha, M.D., Ph.D., Chief Executive Officer of Centessa. Antoine is a true industry leader with significant experience and success as a drug developer, having developed some of the most impactful oncology drugs in the world. I look forward to partnering with him as we advance our portfolio of preclinical programs into the clinic and progress our four assets currently in clinical development.
Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
ii
80% (n=64)
CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response
i Includes patients with =1 postbaseline scan or who discontinued treatment.
ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs too early to be confirmed (n=5).
iii DCR is CR+PR+SD
iv Preliminary PFS limited by earlier censoring by data cutoff due to immature duration of follow-up for 4 and 6 mg/kg dose cohorts.
previously treated HER2-positive advanced gastric cancer AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
In the US, gastric cancer is most frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving beyond five years.
1,2 Approximately one in five gastric cancers are HER2 positive.
3
The approval by the Food and Drug Administration (FDA) was based on the positive results from the randomised DESTINY-Gastric01 Phase II trial conducted in Japan and South Korea. In the trial, Enhertudemonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and objective respo
Search jobs 18-Jan-2021 ADDING MULTIMEDIA ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
First HER2 directed medicine approved for patients with gastric cancer in a decade
TOKYO & MUNICH & BASKING RIDGE, N.J. (BUSINESS WIRE) Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s
ENHERTU
® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
In the U.S., gastric cancer is more frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving five years.